ABLD Stock Overview
Provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ABL Diagnostics Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.86 |
| 52 Week High | €3.18 |
| 52 Week Low | €2.70 |
| Beta | -0.23 |
| 11 Month Change | 0% |
| 3 Month Change | 3.62% |
| 1 Year Change | -70.52% |
| 33 Year Change | 10.00% |
| 5 Year Change | -27.59% |
| Change since IPO | 166.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABLD | FR Trade Distributors | FR Market | |
|---|---|---|---|
| 7D | 0.7% | -1.2% | -0.06% |
| 1Y | -70.5% | 14.3% | -2.5% |
Return vs Industry: ABLD underperformed the French Trade Distributors industry which returned 17% over the past year.
Return vs Market: ABLD underperformed the French Market which returned -2.1% over the past year.
Price Volatility
| ABLD volatility | |
|---|---|
| ABLD Average Weekly Movement | 1.5% |
| Trade Distributors Industry Average Movement | 3.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ABLD has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ABLD's weekly volatility has decreased from 10% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | Chalom Sayada | www.abldiagnostics.com |
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation system, and sanger sequencing reagents. The company also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB.
ABL Diagnostics Société anonyme Fundamentals Summary
| ABLD fundamental statistics | |
|---|---|
| Market cap | €46.09m |
| Earnings (TTM) | €54.36k |
| Revenue (TTM) | €6.19m |
847.8x
P/E Ratio7.4x
P/S RatioIs ABLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABLD income statement (TTM) | |
|---|---|
| Revenue | €6.19m |
| Cost of Revenue | €5.07m |
| Gross Profit | €1.12m |
| Other Expenses | €1.06m |
| Earnings | €54.36k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0034 |
| Gross Margin | 18.06% |
| Net Profit Margin | 0.88% |
| Debt/Equity Ratio | 51.3% |
How did ABLD perform over the long term?
See historical performance and comparison